Optiver Holding B.V. Trims Stock Position in argenex SE $ARGX

Optiver Holding B.V. trimmed its holdings in argenex SE (NASDAQ:ARGX) by 34.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 11,328 shares of the company’s stock after selling 6,066 shares during the period. Optiver Holding B.V.’s holdings in argenex were worth $8,355,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bessemer Group Inc. lifted its stake in shares of argenex by 276.5% in the 3rd quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock valued at $47,000 after purchasing an additional 47 shares during the last quarter. MAI Capital Management raised its holdings in argenex by 866.7% in the 2nd quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after buying an additional 78 shares during the period. Mather Group LLC. acquired a new position in argenex in the third quarter valued at about $50,000. Rossby Financial LCC boosted its stake in argenex by 115.2% during the third quarter. Rossby Financial LCC now owns 71 shares of the company’s stock worth $54,000 after buying an additional 38 shares during the period. Finally, TD Private Client Wealth LLC boosted its stake in argenex by 750.0% during the third quarter. TD Private Client Wealth LLC now owns 85 shares of the company’s stock worth $63,000 after buying an additional 75 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ARGX shares. Morgan Stanley upped their price objective on shares of argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a report on Thursday, December 4th. Wells Fargo & Company upped their price target on argenex from $1,264.00 to $1,317.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Wall Street Zen cut argenex from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. DZ Bank upgraded argenex to a “strong-buy” rating in a report on Friday, December 19th. Finally, Stifel Nicolaus raised their target price on argenex from $1,028.00 to $1,248.00 and gave the company a “buy” rating in a report on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $986.78.

argenex Stock Performance

ARGX stock opened at $840.28 on Wednesday. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The company’s 50 day moving average price is $830.51 and its 200 day moving average price is $810.08. The firm has a market capitalization of $52.00 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 0.71 and a beta of 0.37.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.